Altai Protocol Library New Reference: Amivantamab – Lazertinib for NSCLC with Atypical EGFR Mutations U. Darda Bayraktar, MD 2025-12-08
Altai Protocol Library New Drug: Sevabertinib in Advanced HER2-Mutant NSCLC U. Darda Bayraktar, MD 2025-11-17
Altai Protocol Library New Drug: Sacituzumab Tirumotecan for EGFR-Mutated Advanced NSCLC U. Darda Bayraktar, MD 2025-11-17
Altai Protocol Library New Reference: Rucaparib for Maintenance in Advanced Ovarian Cancer U. Darda Bayraktar, MD 2025-11-17
Altai Protocol Library New Indication: Trastuzumab Deruxtecan with Pertuzumab for First-Line Metastatic Her2-Positive Breast Cancer U. Darda Bayraktar, MD 2025-11-17
Altai Protocol Library New Indication: Neoadjuvant Trastuzumab Deruxtecan For High-Risk her2-Positive Breast Cancer U. Darda Bayraktar, MD 2025-11-17
Altai Protocol Library New Reference: 3 vs 6 Cycles of Chemotherapy for Advanced Urothelial Carcinoma U. Darda Bayraktar, MD 2025-11-17
Altai Protocol Library New Reference: Panitumumab for Ras/Raf WT Metastatic Colorectal Cancer After Anti-EGFR Therapy U. Darda Bayraktar, MD 2025-11-17
Altai Protocol Library New Drug: Ziftomenib for Relapsed/Refractory NPM1-Mutated AML U. Darda Bayraktar, MD 2025-11-16
Altai Protocol Library New Drug: Izalontamab Brengitecan for Metastatic Nasopharyngeal Carcinoma U. Darda Bayraktar, MD 2025-11-15
